Charles River Laboratories have signed an agreement to acquire Citoxlab for $510 million in a deal that aims to expand their global scale and scientific service portfolio.
Researchers have developed a new diagnostic technique to accurately differentiate bladder cancer from benign inflammation using AHNAK2 protein biomarkers.
In this short article one of the organisers of the 23rd International Reid Bioanalytical Forum, Tim Sangster, discusses what this year’s conference has in store from scientific content to social activities.
A novel protein has been discovered that could be a useful blood-based biomarker to monitor the progression of inherited Alzheimer’s disease, over a decade before the clinical symptoms appear.
Researchers from Queen’s University Belfast (UK) have developed a new enzyme biomarker test that has the potential to detect disease and infection.
Researchers have used mass spectrometry to analyze blister fluid in order to aid the diagnosis of burn severity.
A new molecular engineering method, termed TAC-seq, has been developed to enhance the precision of clinical biomarker analysis.
Take a look at our overview of the top events in the world of bioanalysis for January, February and March 2019.
Bristol-Myers Squibb (NY, USA) have announced that they will be acquiring Celgene (NJ, USA) this year for a cost of $74 billion.
Want to find out what happened last year? Editor, Lucy Cliff, highlights the best of 2018’s bioanalytical research in an A–Z round-up.